Feasibility of newly approved nivolumab-ipilimumab combination therapy for unresectable malignant mesothelioma in the Tayside population

被引：0
|
作者：
Wilson, Abbie [1 ]
Smyth, Susan [1 ]
Tough, Fay [1 ]
机构：
[1] Ninewells Hosp & Med Sch, Tayside Canc Ctr, Dundee, Scotland
来源：
LUNG CANCER | 2023年 / 178卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma
    Nakajima, Erica C.
    Vellanki, Paz J.
    Larkins, Erin
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Bi, Youwei
    Qosa, Hisham
    Liu, Jiang
    Zhao, Hong
    Biable, Missiratch
    Hotaki, Lauren Tesh
    Shen, Yuan-Li
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    Donoghue, Martha
    CLINICAL CANCER RESEARCH, 2022, 28 (03) : 446 - 451
  • [2] NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma
    Adler, Amanda I.
    Slayen, Samuel
    Stegenga, Heather
    Guo, Yelan
    Diaz, Richard
    Welton, Nicky J.
    Westwood, Nigel
    Doull, Iolo
    Crawley, Charles
    LANCET RESPIRATORY MEDICINE, 2022, 10 (10): : E92 - E93
  • [3] Immune-Related Esophagitis and Duodenitis Secondary to Nivolumab-Ipilimumab Combination Therapy
    Wang, Susan
    Morales, Shannon
    Ren, Bing
    Drinane, Mary
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1031 - S1032
  • [4] Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma
    Yamazaki, Naoya
    Kiyohara, Yoshio
    Uhara, Hisashi
    Tsuchida, Tetsuya
    Yoshida, Ai
    Yamada, Takako
    Komoto, Akira
    JOURNAL OF DERMATOLOGY, 2023, 50 (09): : 1108 - 1120
  • [5] Effect of Cytotoxic Chemotherapy Following Ipilimumab Puls Nivolumab Combination Therapy for Malignant Pleural Mesothelioma
    Mikami, K.
    Otsuki, T.
    Fujimoto, D.
    Negi, Y.
    Tada, A.
    Higashiyama, T.
    Tokuda, M.
    Kiyota, J.
    Kondo, T.
    Kandori, T.
    Oota, H.
    Murata, T.
    Wakita, H.
    Kato, M.
    Mori, M.
    Takahashi, R.
    Minami, T.
    Kuribayashi, K.
    Kijima, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S410 - S412
  • [6] FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma
    Wright, Kevin
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 502 - 503
  • [7] Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma
    Kondo, T.
    Otsuki, T.
    Kato, M.
    Murata, T.
    Mori, M.
    Ota, H.
    Wakita, H.
    Kandori, T.
    Kiyota, J.
    Higashiyama, T.
    Tokuda, M.
    Tada, A.
    Negi, Y.
    Horio, D.
    Fujimoto, D.
    Mikami, K.
    Takahashi, R.
    Minami, T.
    Kuribayashi, K.
    Kijima, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S276 - S277
  • [8] FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma COMMENT
    Zauderer, Marjorie G.
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 503 - 503
  • [9] New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
    Laune, Quentin
    Brosseau, Solenn
    BULLETIN DU CANCER, 2022, 109 (01) : 4 - 6
  • [10] First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
    Baas, P.
    Scherpereel, A.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mansfield, A.
    Popat, S.
    Jahan, T.
    Antonia, S.
    Oulkhouir, Y.
    Bautista, Y.
    Cornelissen, R.
    Greillier, L.
    Grossi, F.
    Kowalski, D. M.
    Rodriguez-Cid, J.
    Aanur, P.
    Baudelet, C.
    Zalcman, G.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : E42 - E42
12345